Poor medication adherence is both a costly issue for pharma manufacturers – with some estimating a loss of $600 billion each year – and a deadly issue for patients,
Novo Nordisk is working with a digital health start-up to link better medication adherence to lower medicine costs for diabetes patients in the US through a text messaging pilot.
Boehringer Ingelheim has expanded access to a digital adherence programme that helps COPD patients take their medicines as prescribed by offering them educational and motivational tools.
Sanofi is still plugging away with its oral BTK inhibitor tolebrutinib in multiple sclerosis, but has decided to abandon efforts to develop the drug for neuromuscular diso
In the newest episode of the pharmaphorum podcast, editor-in-chief Jonah Comstock speaks with Jameka Hill, senior director of clinical trial health equity at Moderna.